Monte Rosa Therapeutics Inc.
| NASDAQ: GLUE | Healthcare / Biotechnology / USA |
| 7.79 | +0.4300 | +5.84% | Vol 170.19K | 1Y Perf -47.50% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 4.25 | ASK | 8.50 | ||
| Open | 7.40 | Previous Close | 7.36 | ||
| Pre-Market | - | After-Market | 7.79 | ||
| - - | - -% |
| Target Price | 22.33 | Analyst Rating | Strong Buy 1.33 | |
| Potential % | 186.65 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 20.95 | Earnings Rating | — | |
| Market Cap | 384.51M | Earnings Date | 10th May 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.26 | |
| Beta | 1.71 |
Today's Price Range 7.408.05 | 52W Range 5.7415.53 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 15.58% | ||
| 1 Month | 26.46% | ||
| 3 Months | 2.37% | ||
| 6 Months | -4.65% | ||
| 1 Year | -47.50% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -30.64 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -27.28 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -27.39 | |||
Return on invested Capital Q | -8.24 | |||
Return on invested Capital Y | -49.54 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.50 | ||||
| 1.32 | ||||
| - | ||||
| - | ||||
| -5.20 | ||||
| -1.77 | ||||
| 1.32 | ||||
| 6.01 | ||||
| 158.77M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.30 | ||||
| 13.50 | ||||
| 0.13 | ||||
| 0.16 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -0.64 | -0.63 | 1.56 |
| Q03 2022 | -0.61 | -0.58 | 4.92 |
| Q02 2022 | -0.54 | -0.57 | -5.56 |
| Q01 2022 | -0.53 | -0.51 | 3.77 |
| Q03 2021 | -0.46 | -0.43 | 6.52 |
| Q02 2021 | -0.41 | -3.63 | -785.37 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 10th May 2023 |
| Estimated EPS Next Report | -0.69 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 170.19K |
| Shares Outstanding | 49.36K |
| Shares Float | 17.36M |
| Trades Count | 2.37K |
| Dollar Volume | 1.34M |
| Avg. Volume | 108.55K |
| Avg. Weekly Volume | 91.64K |
| Avg. Monthly Volume | 105.34K |
| Avg. Quarterly Volume | 128.68K |
Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) stock closed at 7.79 per share at the end of the most recent trading day (a 5.84% change compared to the prior day closing price) with a volume of 170.19K shares and market capitalization of 384.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 75 people. Monte Rosa Therapeutics Inc. CEO is Markus Warmuth.
The one-year performance of Monte Rosa Therapeutics Inc. stock is -47.5%, while year-to-date (YTD) performance is 2.37%. GLUE stock has a five-year performance of %. Its 52-week range is between 5.74 and 15.525, which gives GLUE stock a 52-week price range ratio of 20.95%
Monte Rosa Therapeutics Inc. currently has a PE ratio of -4.50, a price-to-book (PB) ratio of 1.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -27.28%, a ROC of -27.39% and a ROE of -30.64%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Monte Rosa Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. Monte Rosa Therapeutics Inc.’s next earnings report date is 10th May 2023.
The consensus rating of Wall Street analysts for Monte Rosa Therapeutics Inc. is Strong Buy (1.33), with a target price of $22.33, which is +186.65% compared to the current price. The earnings rating for Monte Rosa Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Monte Rosa Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Monte Rosa Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.72, ATR14 : 0.55, CCI20 : 188.04, Chaikin Money Flow : 0.09, MACD : 0.19, Money Flow Index : 66.65, ROC : 19.30, RSI : 64.22, STOCH (14,3) : 87.79, STOCH RSI : 1.00, UO : 58.60, Williams %R : -12.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Monte Rosa Therapeutics Inc. in the last 12-months were:
Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
CEO: Markus Warmuth
Telephone: +1 617 949-2643
Address: 645 Summer Street, Boston 02210, MA, US
Number of employees: 75
